Latest news with #LupinLtd
Time of India
09-07-2025
- Business
- Time of India
Lupin signs $50 million licensing deal with Zentiva to commercialise Certolizumab Pegol across global markets
Pharma major Lupin Ltd on Wednesday said it has inked a license and supply pact for commercialisation of its biosimilar ' Certolizumab Pegol ' across multiple global markets with the Zentiva Group , entailing milestone receivables of up to USD 50 million. This alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide, Lupin said in a regulatory filing. Under the agreement, Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. On the other hand, Zentiva, a pan-European pharmaceutical firm, will oversee commercialisation activities outside the US and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise, the company added. Lupin will undertake commercialisation in the remaining regions, including the US and Canada, it said. Live Events "Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of USD 10 million upon execution of the agreement and total development and regulatory milestone payments up to USD 50 million," the Indian pharma major said. The profits from the defined markets will be shared between the two companies, it added. Certolizumab Pegol is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn's disease. "Our global development and commercialisation partnership with Zentiva, with its pan-European focus, enables Lupin to commercialise this unique biosimilar in its core markets and through Zentiva in Europe," Lupin President of Corporate Development Fabrice Egros said. Economic Times WhatsApp channel )
Time of India
04-07-2025
- Business
- Time of India
Lupin launches Ipratropium Bromide nasal spray in US
Pharma major Lupin Ltd on Friday said it has launched Ipratropium Bromide nasal spray , used in treatment of runny nose, in the US market. The Ipratropium Bromide nasal solution (nasal spray) launched in the US is of strengths 0.03 per cent and 0.06 per cent, Lupin Ltd said in a regulatory filing. Ipratropium Bromide nasal spray 0.03 per cent and 0.06 per cent are bioequivalent to Atrovent nasal spray in the same strengths of Boehringer Ingelheim Pharmaceuticals , Inc, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Lupin said Ipratropium Bromide nasal spray 0.03 per cent is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide nasal spray 0.06 per cent is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older, it added. Live Events Citing IQVIA MAT May 2025 data, the company said Ipratropium Bromide nasal solution (Atrovent) had estimated annual sales of USD 63 million in the US. PTI
Mint
02-07-2025
- Business
- Mint
Stocks to buy: Lupin, Kalpataru Projects, Max Healthcare, among small-cap, mid-cap stock picks for July
For the month of July, Axis Securities has recommended a selection of mid-cap stocks including Lupin Ltd, Max Healthcare Institute Ltd, Colgate-Palmolive (India) Ltd, Prestige Estates Projects Ltd, and APL Apollo Tubes Ltd, along with small-cap stocks such as Sansera Engineering Ltd and Kalpataru Projects International Ltd. The brokerage is of the opinion that the Indian market began to recover from March 2025, evidenced by a 15% increase in the Nifty 50, and a rise of 25% and 29% in the Mid and Small-cap sectors respectively, since the lows recorded in February 2025. In the past month, the Small-cap index has appreciated by 5.7%, while the Mid-cap index has climbed by 4%, in contrast to the Nifty 50, which has seen a modest rise of 3.1%. Axis Securities believes that the risk-reward scenario is gradually favoring Mid and Small-cap stocks. However, the recovery is expected to be slow and steady as we approach FY26, driven by optimistic earnings projections, enhanced domestic liquidity, and stable macroeconomic conditions in India. In light of this situation, the brokerage continue to prioritize growth at a reasonable price, focusing on 'quality' stocks, monopolistic companies, market leaders in their fields, and sectors and stocks that are oriented towards the domestic market. The brokerage house anticipates that these may outperform the overall market in the near future. According to the brokerage, Lupin is optimistic about its growth trajectory, bolstered by robust new product launches, an expanding portfolio of complex generics, and a strong pipeline. In the US market, the recently introduced Darunavir and Spiriva have captured market shares of 30% and 25%, respectively. The recently launched Tolvaptan (with a market size of $287 million) and Xyway (with a market size of $958 million and 180-day exclusivity) are anticipated to add to revenue in the first half of the year. As per the brokerage, Max Healthcare maintains a balanced revenue mix, with consistent growth observed in both its institutional and international patient segments. The recent increase in the share of institutional business is anticipated to stabilise as more higher-value payer segments develop. Although the launch of new hospitals might initially impact margins, this effect should diminish as these facilities enhance their operational capabilities. Profitability in Lucknow and Nagpur is projected to further improve, supported by rising occupancy rates and the rollout of new clinical programs. The brokerage expressed its appreciation for the company's overarching long-term strategy, which aims to drive revenue growth through several initiatives: 1) Introducing premium science-based products to improve overall realizations, 2) Building the category by boosting awareness through marketing efforts, 3) Enhancing the frequency of consumption and penetration in rural areas, and 4) Broadening the personal care lineup to reduce risks linked to the sluggish growth in the oral care segment. Furthermore, the demand landscape is expected to improve in the upcoming quarters, and the recent decline in stock prices offers a better margin of safety. As a result, they continue to uphold their BUY rating with a new target price of ₹ 2,830/share. Top picks stocks for July Based on brokerage insights, following a lackluster performance in 9MFY25, PEPL's pre-sales surged in Q4FY25, totaling ₹ 6,957 Cr (+48% YoY), fueled by an increase in property launches (14 Mn sq. ft.). The growth primarily resulted from price increases, with additional support from a stronger regional contribution. However, despite this recovery, FY25 pre-sales fell 19% YoY due to postponed launches linked to regulatory challenges, leading to a ~30% shortfall compared to the initial target of ~ ₹ 24,000 Cr. Looking ahead to FY26E, Prestige plans to counter the subdued FY25 results with an extensive launch pipeline valued at ₹ 42,000 Cr. Along with an existing inventory valued at ₹ 21,000 Cr, we believe Prestige is well-equipped to achieve a 65% YoY increase in pre-sales, reaching ₹ 28,000 Cr. As per the brokerage's analysis, the firm aims to increase its capacity to 10 MTPA by FY30, offering a favorable growth opportunity in the long term. We uphold our target price of ₹ 2,035 per share. The stock is currently priced at a 12-month forward price-to-earnings ratio of 38x. The brokerage assesses it with a 12-month forward target multiple of 35x based on our estimated EPS for FY27. As per the brokerage, the firm is poised to take advantage of a strong order backlog, favorable trends in both the domestic and international Transmission & Distribution (T&D) and Building & Factory (B&F) sectors, enhanced performance from its overseas subsidiaries, favorable government policies, and anticipated improvements in margins. It is expected to achieve a compound annual growth rate (CAGR) of 18%/22%/41% for the period from FY25 to FY27E. Based on the brokerage's analysis, considering factors such as a) a larger proportion of sales in Non-Automotive ICE components, b) a rising trend toward premium products, c) a dedicated focus on enhancing margin performance, d) a strong capability to generate operating cash flow, and e) plans for capacity expansion, we anticipate that Revenue, EBITDA, and PAT will experience a CAGR of 17%, 21%, and 30%, respectively, from FY25 to FY27E. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
26-06-2025
- Business
- Time of India
Lupin launches generic chronic constipation treatment drug in US
Pharma major Lupin Ltd on Thursday said it has launched its generic version of Prucalopride tablets used to treat chronic idiopathic constipation in the US market after the recent approval by the country's health regulatory. The Mumbai-based company has launched Prucalopride tablets of strengths 1 mg, and 2 mg in the US, following the recent approval of its abbreviated new drug application (ANDA) from the USFDA, Lupin said in a regulatory filing. These Prucalopride tablets are bioequivalent to Motegrity tablets , 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc and are indicated for the treatment of chronic idiopathic constipation (CIC) in adults, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Citing IQVIA MAT April 2025 data, the company said Prucalopride tablets, 1 mg and 2 mg, had estimated annual sales of USD 184 million in the US.
Business Standard
17-06-2025
- Business
- Business Standard
Quick Wrap: Nifty Pharma Index declines 1.89%
Nifty Pharma index ended down 1.89% at 21622.8 today. The index is down 0.00% over last one month. Among the constituents, Granules India Ltd slipped 3.39%, Lupin Ltd shed 3.33% and Natco Pharma Ltd dropped 3.27%. The Nifty Pharma index is up 9.00% over last one year compared to the 5.91% surge in benchmark Nifty 50 index. In other indices, Nifty Metal index is down 1.43% and Nifty Commodities index is down 0.77% on the day. In broad markets, the Nifty 50 is down 0.37% to close at 24853.4 while the SENSEX is down 0.26% to close at 81583.3 today.
